Terazosin Hydrochloride
Product Images NDC 53808-0930

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Terazosin Hydrochloride (NDC 53808-0930). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by State Of Florida Doh Central Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Terazosin HCl 2 mg Caps (Terazoin 2mg(apotex))

Packaging label for Terazosin Hydrochloride 2 mg capsules, prescription only, with a quantity of 30 capsules. The label also includes lot number JC7945, expiration date 01/31/10, and indicates packaging by DOH Central Pharmacy in Tallahassee, FL.*

FDA Label Image

Terazosin HCl 5 mg Caps (Terazosin 5mg(apotex))

Label for Terazosin Hydrochloride 5 mg capsules, prescription only, quantity 30. Labeled by State of Florida DOH Central Pharmacy, Tallahassee, FL. Includes lot number JF3880, expiration date May 31, 2010, and UPC barcode.*

FDA Label Image

Terazosin HCl 1 mg Caps (Terazosin1mg (apotex))

Label for Terazosin Hydrochloride 1 mg tablets, quantity 30, packaged by DOH Central Pharmacy, Tallahassee, FL. Includes lot number, expiration date, and a barcode.*

FDA Label Image

Chemical Structure (Terazosin Hydrochloride Capsules 1)

Chemical structure of Terazosin Hydrochloride, depicting the molecular arrangement of carbon, hydrogen, nitrogen, and oxygen atoms, including the hydrochloride salt component, with the molecular formula C19H25N5O4 · HCl shown below the structure.*

FDA Label Image

Figure 1 (Terazosin Hydrochloride Capsules 2)

A two-part line graph labeled 'Figure 1, Study 1' showing comparative data between Terazosin and Placebo. The left graph displays the mean change in total symptom score from baseline over 3 months, with Terazosin showing a greater decrease. The right graph shows mean increase in peak flow rate (mL/sec) from baseline over 3 months, with Terazosin demonstrating a larger increase than Placebo. Sample sizes are indicated (around 50 per group).*

FDA Label Image

Figure 2 (Terazosin Hydrochloride Capsules 3)

A line graph titled 'Mean Change in Total Symptom Score from Baseline' illustrating data from a long-term, open-label, non-placebo controlled study with 494 participants. The x-axis represents months from 0 to 30, and the y-axis represents mean change from baseline values ranging approximately from 0 to -7. Two data series are plotted, both showing a downward trend in symptom scores over time, with several points marked as statistically significant compared to baseline.*

FDA Label Image

Figure 3 (Terazosin Hydrochloride Capsules 4)

Line chart titled 'Mean Change in Peak Flow Rate from Baseline' from a long-term, open-label, non-placebo controlled study involving 494 participants. The y-axis shows mean change from baseline in ml/sec, and the x-axis shows time in months up to 30 months. Data points indicate statistically significant increases (p ≤ 0.05) at various time points compared to baseline.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.